Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
Walgreens recalls sits at the center of this dementia and brain health question.
No current FDA recall of a Walgreens sleep aid has been issued specifically because the agency linked the product to dementia cases. However, this topic intersects two important healthcare developments that deserve your attention: the March 2025 Unisom SleepMelts recall at Walgreens (due to nitrosamine contamination) and emerging research showing that certain over-the-counter sleep aids containing anticholinergic ingredients may increase dementia risk in older adults. While the FDA hasn’t officially recalled a sleep aid for dementia concerns, the scientific evidence connecting some sleep medications to cognitive decline is real and growing, which is why understanding these risks matters for anyone managing sleep issues in later life.
The confusion likely stems from the fact that research has identified a genuine link between anticholinergic sleep aids and dementia—a connection strong enough that health organizations are taking notice. But there’s an important distinction: research showing risk is different from an FDA enforcement action recalling a product. This article explores what’s actually happening, what the evidence shows, and what you should know if you or a loved one uses sleep aids while managing brain health concerns.
Table of Contents
- What Sleep Aids Have Actually Been Recalled, and Why?
- The Research Connection Between Anticholinergic Sleep Aids and Dementia Risk
- Why Sleep Aids and Dementia Risk Matter for Older Adults
- How to Evaluate Sleep Aid Safety If You’re Managing Dementia Risk
- What About Other Sleep Aid Ingredients and Risks?
- The Unisom Recall and What It Teaches Us About Sleep Aid Safety
- Looking Forward: How Awareness of Sleep Aid Risks Is Changing
- Conclusion
What Sleep Aids Have Actually Been Recalled, and Why?
The most recent sleep aid recall affecting Walgreens customers was the March 2025 Unisom SleepMelts recall, which involved 180,696 packages sold nationwide. Unisom, a popular over-the-counter sleep aid containing doxylamine succinate, was pulled from shelves because of nitrosamine impurity contamination—a manufacturing issue unrelated to dementia. Nitrosamines are potentially cancer-causing contaminants that can form during the drug manufacturing process if quality controls slip.
The fda classified this as a Class II recall, meaning the product could cause temporary or reversible adverse health effects but is unlikely to cause serious harm. This distinction is crucial: Walgreens and other retailers had to remove Unisom because of what got into the product during manufacturing, not because of what the active ingredient itself does to the brain over time. The recall addressed an immediate chemical contamination problem, not the slower, long-term cognitive risks associated with the medication’s core ingredient. Understanding this difference helps explain why you haven’t seen a major FDA announcement linking a Walgreens sleep aid recall to dementia—the regulatory action exists for one reason, while the scientific concern about dementia risk exists independently.
The Research Connection Between Anticholinergic Sleep Aids and Dementia Risk
The real story here involves anticholinergic compounds, which are found in many over-the-counter sleep aids including Unisom. Anticholinergics block the neurotransmitter acetylcholine, which plays a critical role in memory and cognition. Multiple studies have shown that long-term use of anticholinergic medications is associated with cognitive decline and increased dementia risk, particularly in adults over 65. One significant finding showed that people 65 and older who used anticholinergic sleep aids regularly had up to a 78% higher risk of developing dementia compared to non-users.
However—and this is an important limitation—this research shows association and increased risk, not causation. These studies cannot prove that the sleep aid itself caused the dementia; other factors could be at play, or people with early cognitive decline might be more likely to use sleep aids. Additionally, most of this research focuses on long-term, regular use, not occasional use. A person taking Unisom once or twice a week faces a different risk profile than someone taking it nightly for years. The FDA hasn’t issued a recall based on dementia concerns because the evidence, while compelling, doesn’t meet the threshold for saying “this product is so clearly causing harm that it must be removed from the market immediately.”.
Why Sleep Aids and Dementia Risk Matter for Older Adults
For people already at risk of cognitive decline—whether because of family history, existing mild cognitive impairment, or age—the choice of sleep aid becomes more consequential. Many older adults struggle with insomnia, and the pressure to find a quick fix can lead to reaching for over-the-counter options without fully considering long-term brain health implications.
Walgreens shelves are stocked with anticholinergic sleep aids that are effective in the short term but may carry risks that don’t show up immediately. The challenge is that safer alternatives exist but require more work: melatonin, valerian root, or prescription medications designed with fewer cognitive side effects are options, but they’re not always as immediately effective or as convenient as grabbing a familiar box of Unisom. This is where the real recall story matters—not because Walgreens is pulling products off shelves for dementia reasons, but because informed consumers should know that the ease of an over-the-counter sleep aid comes with potential cognitive costs that add up over months and years of use.
How to Evaluate Sleep Aid Safety If You’re Managing Dementia Risk
If you’re someone managing brain health concerns, the first step is to review any sleep aids you’re currently using with your doctor or pharmacist, specifically asking whether the product contains anticholinergic ingredients. Common over-the-counter sleep aids with anticholinergic properties include products with doxylamine (like Unisom) and diphenhydramine (like Benadryl). Your healthcare provider can help you weigh the immediate benefit of better sleep against the longer-term risk profile, considering your specific age, health status, and family history of cognitive decline.
For those who need ongoing sleep support, non-anticholinergic alternatives include melatonin (though evidence for effectiveness is mixed), prescription medications like trazodone or melatonin receptor agonists, and behavioral approaches like cognitive behavioral therapy for insomnia (CBT-I). While prescription options aren’t automatically safer, they’re designed with specific populations in mind and can be monitored more closely by your doctor. The tradeoff is that these alternatives may require more time to work, cost more, or involve more frequent doctor visits—but for someone prioritizing long-term brain health, these inconveniences may be worth it.
What About Other Sleep Aid Ingredients and Risks?
Not all sleep aids carry the same dementia risk. Natural ingredients like valerian root and chamomile have minimal anticholinergic activity and limited evidence of cognitive harm, though their effectiveness for sleep is also more modest and less consistent than pharmaceutical options. Melatonin, the hormone that regulates sleep-wake cycles, works through a different mechanism and hasn’t been linked to dementia risk in the same way, though long-term safety data for older adults remains limited.
A critical warning: just because something is labeled “natural” or available over-the-counter doesn’t mean it’s risk-free, particularly for aging brains. Some herbal sleep aids can interact with other medications, and the quality and dosage in over-the-counter products can vary widely between manufacturers. If you’re taking other medications—especially those for heart conditions, blood pressure, or cognitive issues—you need to discuss sleep aid options with your pharmacist, not just rely on product labels or reviews.
The Unisom Recall and What It Teaches Us About Sleep Aid Safety
The Unisom recall from March 2025 offers a practical lesson about over-the-counter medication safety that extends beyond just that one product. Contamination and manufacturing issues can affect any over-the-counter product, which is why checking the FDA’s drug recall website periodically is smart if you regularly use any medication, including sleep aids. The recall affected Unisom specifically, but similar products made by other manufacturers could have faced similar issues—or could in the future.
If you were using Unisom before the recall, it’s worth checking whether your batch was included (the FDA website lists specific lot numbers). More broadly, this recall illustrates why consistency in where you purchase medications matters. Getting products from established retailers like Walgreens, CVS, or major grocery store pharmacies generally means better supply chain oversight than purchasing from lesser-known online sellers, though no source is completely immune to contamination risks.
Looking Forward: How Awareness of Sleep Aid Risks Is Changing
Healthcare providers and public health agencies are increasingly aware of the dementia risk associated with anticholinergic medications, including sleep aids. While the FDA hasn’t issued a broad recall based on dementia concerns, we may see stronger warnings, more research, or shifts in how these products are marketed and sold—particularly as the population ages and dementia becomes a more prominent health concern.
Some experts have called for clearer labeling that warns older adults specifically about cognitive risks, similar to how anticholinergic medications are already flagged in geriatric prescribing guidelines. For now, the takeaway isn’t that you should panic about Walgreens sleep aids, but rather that you should be informed and deliberate about your choices. The medication landscape continues to evolve as evidence accumulates, and staying aware of both recalled products and emerging research helps you make better decisions about your brain health.
Conclusion
No FDA recall of a Walgreens sleep aid has been issued specifically linking the product to dementia cases caused by the FDA. However, the real story is more nuanced: anticholinergic sleep aids like Unisom do carry research-backed risks of cognitive decline and dementia in older adults, and the March 2025 Unisom recall (while addressing contamination, not dementia risk) removed a popular product from shelves.
Understanding the difference between what’s been officially recalled and what research shows as risky helps you make informed choices about sleep management. If you or a loved one is struggling with sleep while also concerned about brain health, the path forward involves honest conversations with your doctor about your specific risks, exploration of alternatives that don’t carry anticholinergic properties, and regular awareness of both FDA recalls and evolving research on medication safety. Brain health is a long-term investment, and choosing sleep solutions that prioritize your cognitive future—even if they’re less convenient in the short term—is a choice worth making.
You Might Also Like
- FDA Issues Warning About Common Sleep Aid Linked to Dementia Risk
- University of Colorado Identifies Common Sleep Aid That Increases Dementia Risk by 79 Percent
- University of Wisconsin Links Late Life Depression to 65 Percent Higher Dementia Risk
For more, see Alzheimer’s Association.
